Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Participants with type 2 diabetes mellitus diagnosed for at least 1 year before the screening visit, treated for at least 3 months prior to visit 1 with metformin alone or metformin and a second oral anti-diabetic treatment that could be a sulfonylurea, a glinide, a sodium glucose co-transporter-2 inhibitor or a di-peptidyl peptidase 4 (DPP-4) inhibitors, and who were not adequately controlled with this treatment.~* Signed written informed consent.~Exclusion criteria:~* HbA1c at screening visit:~  * less than 7.5% or more than 10% for participants previously treated with metformin alone,~ * less than 7.0% or more than 9% for participants previously treated with metformin and a second oral anti-diabetic treatment.~* Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.~* Use of oral glucose-lowering agents other than those stated in the inclusion criteria or any injectable glucose-lowering agents during the 3 months before screening.~* Previous Treatment with insulin (except for short-term treatment due to intercurrent illness including gestational diabetes, at the discretion of the trial physician).~* History of discontinuation of a previous treatment with a glucagon-like peptide (GLP-1) receptor agonist (GLP-1 RA) due to safety/tolerability issue or lack of efficacy.~* Participant who previously participated in any clinical trial with lixisenatide or the insulin glargine/lixisenatide fixed ratio combination or had previously received lixisenatide.~* Any contraindication to metformin use, according to local labeling.~* Use of weight loss drugs within 3 months prior to screening visit.~* Within the last 6 months prior to screening visit: history of stroke, myocardial infarction, unstable angina, or heart failure requiring hospitalization. Planned coronary, carotid or peripheral artery revascularisation procedures to be performed during the study period.~* History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy was already performed), chronic pancreatitis, pancreatitis during a previous treatment with incretin therapies, pancreatectomy, stomach/gastric surgery.~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (e.g, multiple endocrine neoplasia syndromes).~* Uncontrolled or inadequately controlled hypertension (systolic blood pressure above 180 mmHg or diastolic blood pressure above 95 mmHg) at screening visit.~* At screening visit, Body Mass Index (BMI) less than or equal to 20 or above 40 kg/m\^2.~* At screening visit amylase and/or lipase more than 3 times the upper limit of the normal (ULN) laboratory range.~* At screening visit alanine aminotransferase (ALT) or alkaline phosphatase (AST) more than 3 ULN.~* At screening visit calcitonin above or equal to 20 pg/mL (5.9 pmol/L).~Exclusion Criteria for randomization at the end of the screening period:~* HbA1c less than 7% or above 10%;~* Fasting Plasma glucose above 250 mg/dL (13.9 mmol/L);~* Metformin maximal tolerated dose less than 1500 mg/day;~* Amylase and/or lipase more than 3 ULN.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) (Type: EXPERIMENTAL): FRC once daily (QD) for 30 weeks. Dose individually adjusted.
- Insulin Glargine (Type: ACTIVE_COMPARATOR): Insulin glargine QD for 30 weeks. Dose individually adjusted.
- Lixisenatide (Type: ACTIVE_COMPARATOR): Lixisenatide 10 mcg QD for 2 weeks, then 20 mcg QD (maintenance dose).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete